Centrum Badan Klinicznych Pi-House Sp. z o.o. — Clinical Trial Site

120 Registered trials

44 Currently recruiting

Organisation

Centrum Badan Klinicznych Pi-House Sp. z o.o.

Location

Gdansk, Poland

Identifier

ORG-100040967

Address

Ul. Na Zaspe 3, 80-546, Poland

Departments

-
#5752: Dermatologia i Wenerologia
#7001; N/A
2656: Dermatologia i Wenerologia
40637: Dermatology
Centrum Badań Klinicznych PI-House
Centrum badan Klinicznych PI-House sp. z o.o
Centrum Badan Klinicznych Pi-House Sp. z o.o.
Centrum Badan Klinicznych PI-House sp. z o.o. Loc. 6
Centrum Badan Klinicznych PIHouse
Centrum Badan Klnicznych
Chronic pain
dermatology
Dermatology Department
N/A
NA
ND
No Department
not applicable
Private practice
Psychiatria
Psychiatry

Clinical trials at this site (120)

Search interface

A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Schizophrenia 4 2021-09-20
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Su… Recruiting

2024-520058-39-00 Plaque Psoriasis 4 2020-12-28
A Phase 1/2 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Ended

2024-519005-35-00 Type 2 Diabetes Mellitus 7 2026-03-09
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Alzheimer Disease Dementia Brain Diseases Central 5 2025-12-04
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen… Ended

2024-513572-17-00 Generalized Anxiety Disorder (GAD) 5 2025-08-20
A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended

2024-519370-40-00 Alopecia areata 5 2025-07-16
A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended

2024-519561-22-00 Obesity 4 2025-07-07
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended

2024-515672-12-00 Moderate to Severe Genital Psoriasis 5 2025-05-27
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat… Ended

2024-513348-27-00 Plaque psoriasis 5 2025-05-09
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Treatment-resistant depression 5 2024-02-09